| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BACKGROUND: The effect of melatonin on the intraoperative requirements for IV anesthetics has not been documented. We studied the effect of melatonin premedication on the propofol and thiopental doseresponse curves for abolition of responses to verbal commands and eyelash stimulation. METHODS: This prospective, randomized, double-blind study included 200 adults with ASA physical status I. Patients received either 0.2 mg/kg melatonin or a placebo orally for premedication (n = 100 per group). Approximately 50 min later, subgroups of 10 melatonin and 10 placebo patients were administered various doses of propofol (0.5, 1.0, 1.5, 2.0, or 2.4 mg/kg) or thiopental (2.0, 3.0, 4.0, 5.0, or 6.0 mg/kg) for anesthetic induction. The ability of each patient to respond to the command, "open your eyes," and the disappearance of the eyelash reflex were assessed 60 s after the end of the injection of propofol or thiopental. Doseresponse curves were determined by probit analysis. RESULTS: Melatonin premedication decreased thiopental ED50 values for loss of response to verbal command and eyelash reflex from 3.4 mg/kg (95%confidence interval, 3.23.5 mg/kg) and 3.7 mg/kg (3.53.9 mg/kg) to 2.7 mg/kg (2.62.9 mg/kg) and 2.6 mg/kg (2.52.7 mg/kg), respectively (P < 0.05). Corresponding propofol ED50 values decreased from 1.5 mg/kg (1.41.6 mg/kg) and 1.6 mg/kg (1.51.7 mg/kg) to 0.9 mg/kg (0.80.96 mg/kg) and 0.9 mg/kg (0.80.95 mg/kg), respectively (P < 0.05). CONCLUSIONS: Melatonin premedication significantly decreased the doses of both propofol and thiopental required to induce anesthesia.
The pineal hormone melatonin (N-acetyl-5-methoxytryptamine) regulates a variety of physiological processes, including circadian, cardiovascular, reproductive, and neuroendocrine functions, and enhances immune responses (13). However, it is the hypnotic effects of melatonin that are considered an integral component of its physiological role (4,5). Administration of melatonin facilitates sleep onset and improves the quality of sleep (68). Premedicants decrease the intraoperative requirements for IV anesthetics (911). Although we previously demonstrated that melatonin is an effective premedicant in both adult and pediatric surgical patients (1214), the effect of melatonin on the requirements of IV anesthetics to induce anesthesia has not been documented. To that end, we designed and performed a prospective, randomized, double-blind study to evaluate the effect of melatonin premedication on the doseresponse curves of propofol and thiopental calculated for the two commonly used end-points: abolition of response to verbal commands and loss of eyelash reflex.
After obtaining IRB approval from King Khalid University Hospital (Riyadh, Saudi Arabia) and written informed patient consent, we enrolled 200 adult patients of both sexes who met the criteria for ASA physical status I. Patients who had taken benzodiazepines, opioid drugs, or other sedative drugs within 1 mo of the planned date of surgery were excluded. Patients were randomly assigned to four groups (n = 50 patients per group) (according to a computer-generated list) based on whether they would receive 0.2 mg/kg melatonin premedication or placebo (saline) and the type of induction drug used (propofol or thiopental). The randomization list was maintained by the pharmacy. Before surgery, patients were transported to an isolated, quiet room in the operating suite. A pulse oximeter probe was placed on each patient, and blood oxygen saturation, arterial blood pressure, and heart rate were recorded continuously. The melatonin (Sigma Chemical, St Louis, MO) and placebo (saline) solutions were prepared by a pharmacist to a fixed volume of 3 mL in a syringe from which the needle had been removed and marked only with a coded label to maintain the double-blind nature of the study. The contents of the syringe were given sublingually approximately 50 min before the induction of general anesthesia by a resident not involved in the management of the patient or in data collection. The patient was first asked to touch the tip of the tongue to the back of the upper teeth. The drug was then placed under the tongue, and the patient was asked to close his or her mouth without swallowing. After 180 s, the patient was permitted to swallow the medication. A visual analog scale (VAS) was used to evaluate the patients anxiety. The scale was a 50-cm long and 10-cm high card that was divided diagonally into a white triangle and a bright red triangle. A centimeter scale was marked on the back of the card (15,16). The white end was marked "no anxiety," and the red end was marked "anxiety as bad as ever can be." One investigator blinded to group assignment performed all test scoring in the perioperative period. The same investigator evaluated anxiety VAS score, orientation score (0 = none; 1 = orientation in either time or place; 2 = orientation in both), and sedation score (1 = awake; 2 = drowsy; 3 = asleep, but arousable; 4 = asleep and not arousable) before the administration of premedication and approximately 50 min later (on arrival of the patient in the operating room). In the operating room, the following predetermined doses of drugs were administered to subgroups of 10 patients each: propofol at 0.5, 1.0, 1.5, 2.0, or 2.4 mg/kg; or thiopental at 2.0, 3.0, 4.0, 5.0, or 6.0 mg/kg. The attending anesthesiologist was unaware of the premedication or induction medication used. Because propofol in aqueous emulsion is a milky substance that can be easily distinguished from thiopental, all syringes were taped to prevent the observer from seeing their contents. Standard intraoperative monitoring was used. All drugs were injected over 15 s into a rapidly flowing IV infusion. The disappearance of the patients ability to respond to the command, "open your eyes," and the disappearance of the eyelash reflex were assessed by one investigator blinded to premedication and induction medication used 60 s after the end of the injection of propofol or thiopental. These outcomes were used as end points for induction of anesthesia. Thereafter, additional doses of propofol or thiopental were administered to ensure an adequate depth of anesthesia, and anesthesia was maintained with oxygennitrous oxideisoflurane and fentanyl titrated to maintain a bispectral index value in the range of 40. The times from premedication to induction of anesthesia (start of injection of propofol or thiopental) and the duration of anesthesia were noted. Recovery times to a score of 8 on the modified Aldrete scale (17) were noted.
Demographic data were analyzed with analysis of variance,
This study included 200 patients aged 1850 yr (mean ± sd, 33.2 ± 9.2 yr) and weighing 5195 kg (73.9 ± 10.9 kg). Patients in the four treatment groups were comparable with respect to age, sex distribution, weight, height, premedication-induction time, duration of anesthesia, and time to modified Aldrete scale score of 8 (Table 1).
There were no differences between the melatonin and placebo groups in baseline anxiety VAS scores (median 29 [range 1048] vs 30, [547] respectively), sedation scores (1 [11] for both groups), or orientation scores (2 [22] for both groups). On arrival in the operating room, patients who received melatonin premedication were more sedated (sedation score, 2 [13]) and less anxious (VAS, 10 [627]) than those who received placebo (1 [12] and 27, [346] respectively; P < 0.0001 for both comparisons). There was no difference in orientation scores between the two groups, although eight patients (8%) in the melatonin group were not orientated in either time or place. The calculated ED50 and ED90 doses are shown in Table 2. Melatonin premedication significantly enhanced the effects of both propofol and thiopental, resulting in significantly lower ED50 and ED90 values. In addition, melatonin premedication shifted all dose response curves to the left (Figs. 1 and 2), and the slopes of the doseresponse curves of propofol and thiopental differed significantly between the placebo and melatonin groups (Table 2).
The results of the present study confirm our earlier findings that melatonin is an effective premedicant (1214). Here, oral premedication with 0.2 mg/kg melatonin approximately 50 min before induction of anesthesia significantly reduced preoperative anxiety and increased sedation without impairing orientation, and significantly decreased the dose requirements for propofol and thiopental at end points commonly used for induction of anesthesia. At the ED50 values reflecting loss of responses to verbal command and eyelash reflex, the relative potency of propofol after melatonin premedication was 1.71.8 times greater than that of propofol after the administration of placebo. Similarly, the relative potency of thiopental was 1.31.4 times greater after premedication with melatonin than that of thiopental after placebo. The ED50 values of thiopental alone and propofol alone for loss of response to verbal command in this study were comparable to the previously reported values of 23 mg/kg for thiopental (1821) and 1.11.34 mg/kg for propofol (9,19,2123).
Premedication with IV midazolam has been shown to enhance the effects of thiopental and propofol (9,11,2325). For example, in one study, premedication with 0.02 mg/kg midazolam decreased the ED50 for thiopental from 2.4 to 1.6 mg/kg. (24) This enhancement has been attributed to the effect of the interaction between midazolam and thiopental or propofol on In accordance with our results, orally administered melatonin in rats has been shown to enhance the anesthetic effects of thiopental and ketamine (30). In mammals, melatonin activates two G-protein-coupled melatonin membrane receptors, MT1 and MT2 (31,32). There is evidence that the hypnotic activity of melatonin is also linked to the GABAA receptor (33,34). Several studies have shown that melatonin increases in vivo GABA accumulation in the rat brain (35), binds to GABAA receptors (36), enhances GABAA receptor-mediated current (37), and enhances [3H]GABA binding to GABAA receptors (38). In humans, normal melatonin production is about 28.8 µg/day (39), and its half-life is relatively short (approximately 20 min) (40). Oral administration of 80 mg melatonin results in peak serum melatonin concentrations 35010,000 times more than those occurring physiologically at nighttime within 60150 min after ingestion with an elimination half-life of 48 min (41). Oral administration of smaller doses of 15 mg of melatonin result in lower serum melatonin concentrations, but still 10100 times more than that observed at nighttime (42). The present study demonstrated that melatonin premedication significantly reduces the doses of both propofol and thiopental required for loss of responses to verbal commands and eyelash stimulation.
Accepted for publication August 17, 2006. Supported by institutional and/or departmental sources. The results of this study were presented at the ASA Annual Meeting, Chicago, Illinois, October 1418, 2006.
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|